Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma

2020 ◽  
Vol 22 (12) ◽  
pp. 2324-2332
Author(s):  
G. He ◽  
X. Liu ◽  
X. Pan ◽  
Y. Ma ◽  
X. Liu
Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2414
Author(s):  
Afshin Derakhshani ◽  
Shahryar Hashemzadeh ◽  
Zahra Asadzadeh ◽  
Mahdi Abdoli Shadbad ◽  
Farnaz Rasibonab ◽  
...  

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory immune checkpoint that can be expressed in tumor-infiltrating lymphocytes and colorectal cancer (CRC) cells. This immune checkpoint can attenuate anti-tumoral immune responses and facilitate tumor growth and metastasis. Although capecitabine is an effective chemotherapeutic agent for treating CRC, its effect on the tumoral CTLA-4 expression remains unclear. In the current research, we applied the GSE110224 and GSE25070 datasets to characterize CTLA-4 expression in CRC patients. Then, we analyzed CTLA-4 expression in CRC samples, HT-29, HCT-166, and SW480 cell lines using real-time PCR. Our bioinformatic results have highlighted the overexpression of CTLA-4 in the CRC tissues compared to the adjacent non-tumoral tissues. Our in vitro studies have indicated that SW480 cells can substantially overexpress CTLA-4 compared to HT-29 and HCT 116 cells. In addition, capecitabine can remarkably downregulate the expression of CTLA-4 in SW480 cells. Collectively, capecitabine can inhibit the expression of CTLA-4 in CRC cells and might bridge the immunotherapy approaches with chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document